MDCX · Medicus Pharma Ltd.
$0.17
0.00 (-2.33%)
At close · Sep 8
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$10.87M
Shares
63.18M
MDCX metrics
45 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.17
Market cap
$10.87M
Price action
19 metricsPrice change (1W)
-33.3%
Price change (30D)
-46.6%
Price change (3M)
-50.9%
Price change (6M)
-55.6%
Price change (YTD)
-88.8%
Price change (1Y)
-90.6%
Trailing year
Price change (5Y)
—
52-week high
$2.80
52-week low
$0.17
Change from 52-week high
-93.9%
Change from 52-week low
+0.9%
Annualized volatility
130.2%
Beta
1.9
RSI (14D)
27.7
Price vs SMA 50
-47.6%
Price vs SMA 200
-78.0%
Avg volume (3M)
3.30M
Relative volume
4.8
Average dollar volume
$846,818
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
63.18M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-521.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$43.29M
Net income (TTM)
−$56.66M
Trailing 12 months
Diluted EPS (TTM)
$-2.41
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+285.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-209.0%
Debt / equity
—
Current ratio
1.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$15.17M
Total assets
$27.12M
Total debt
$2.34M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$29.32M
Capital expenditures (TTM)
—
R&D (TTM)
$11.89M
SG&A (TTM)
—
Stock compensation (TTM)
$3.29M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
27
13F filer change QoQ
+2
Institutional ownership
4.3%
Short interest
3 metricsShort interest
4.4%
Latest settlement · 1.6 days to cover
Days to cover
1.6d
Short-squeeze score
51 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged